This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Glassia (IV)

Shire Pharmaceuticals Group PLC

Drug Names(s): AAT-IV, Intravenous Alpha-1-Antitrypsin (AAT), Kamada API

Description: BioMedTracker maintains separate drug profiles for the inhaled (IH) and intravenous (IV) formulations of Alpha 1-Antitrypsin (AAT).

Kamada has developed a high purity, liquid, ready-to-use human plasma derived AAT for the treatment of alpha-1 antitrypsin deficiency (AATD). AATD is a shortage or absence of a protein, A-1 Antitrypsin, that blocks the destructive effects of certain enzymes. Lack of this protein can lead to the destruction of lung tissue and cause chronic lung disease such as emphysema.

Enzymatic assays in diabetic patients have shown that diabetes is associated with reduced trypsin capacity of plasma. AAT facilitates alloimmune-tolerance, and its anti-inflammory properties has anti-apoptotic effects on beta cells.

Deal Structure: Drug revenue splits are BioMedTracker estimates.

Baxter and Kamada
In August 2010, Baxter announced a definitive agreement with Kamada for exclusive commercial rights to Glassia in the United States, Australia, New Zealand and Canada. The distribution agreement includes an upfront cash payment by Baxter of $20 million. The agreement also includes a provision under which Kamada has agreed, for a limited period of time, not to initiate or enter any discussions or agreements relating to the commercialization of GLASSIA in certain other geographies. Under a separate license agreement, Baxter has been granted the right to process GLASSIA and will seek necessary regulatory approvals to enable it to do so. Also under this agreement, Baxter may make additional payments of up to $25 million related to the achievement of certain commercial milestones and the execution of a technology transfer related to the production of the therapy by Baxter, as well as royalties on product...See full deal structure in Biomedtracker

Partners: Kamada Ltd. Chiesi Farmaceutici S.p.A.

Glassia (IV) News

Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug